Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket: cilengitide, intetumumab, abituzumab | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 231 | 0.85 |
| pathways Reactome | 7 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 8900
Sealed predictions
- ITGB5 in dopamine neurons, braak-0.77 (p 0.015) → -0.46 (p 0.209)receipt 8908
Swarm cases
receipt 8908: ITGB5 in dopamine neurons, braak
- power
- full sample -0.62 (p 0.0057, n 18), 95% CI -0.84 to -0.22. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.57 (p 0.014, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.76 (p 2.4e-4, n 18). not the mix.
- skeptic
- leave-one-out range -0.72 to -0.58, sign flips 0; without severely affected donors -0.62 (p 0.0057, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ITGB5 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts